<DOC>
	<DOC>NCT01019616</DOC>
	<brief_summary>The purpose of this phase Ⅲ, multi-center, prospective, open-label, randomized,controlled study is to determine whether alternative non-cross-resistant adjuvant chemotherapy can increase distant disease free survival(DDFS) in operable patients non-response to primary chemotherapy.</brief_summary>
	<brief_title>Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Female patients, age ≦65 years Biopsy proven lymph node positive, estrogen receptor positive primary breast cancer Must have completed a 4cycle neoadjuvant chemotherapy with a standard regimen(containing anthracycline or paclitaxel) Must have undergone surgery to remove the primary tumor by either a mastectomy or enlarged local excision Postoperative residual positive lymph nodes or G1/G2/G3 of Miller &amp; Payne Grading System Adequate recovery from recent surgery No history of other malignancies No currently uncontrolled diseased or active infection Not pregnant or breast feeding, and on appropriate birth control if of childbearing potential Adequate cardiovascular function reserve with a myocardial infarction within the past six month Adequate hematologic function with: 1. Absolute neutrophil count (ANC) ≥1500/mm3 2. Platelets ≥100,000/ mm3 3. Hemoglobin ≥10 g/dL Adequate hepatic and renal function with: 1. Serum bilirubin ≤1.5×UNL 2. Alkaline phosphatase and alanine aminotransferase (ALT) ≤2.5 x ULN. (≤5 x ULN is acceptable in the setting of hepatic metastasis) 3. BUN between 1.7 and 8.3 mmol/L 4. Cr between 40 and 110 umol/L Knowledge of the investigational nature of the study and Ability to give informed consent Ability and willingness to comply with study procedures. Known or suspected distant metastases Concurrent malignancy or history of other malignancy Uncontrolled diseases(e.g., heart failure, myocardial infarction within 6 months, arrhythmia, unstable diabetes, hypercalcemia) or active infection Geographical, social, or psychological problems that would compromise study compliance Known or suspected hypersensitivity to anthracycline or paclitaxel</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>